A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2014
At a glance
- Drugs Mavoglurant (Primary)
- Indications Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Novartis
- 22 Nov 2011 Actual end date (5 Jul 2011) added as reported by European Clinical Trials Database record.
- 16 Nov 2011 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 25 May 2011 New trial record